These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 20169511

  • 1. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B, van Heerde WL, Laros-van Gorkom BA.
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [Abstract] [Full Text] [Related]

  • 2. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
    Meijer P, Verbruggen B.
    Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B.
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [Abstract] [Full Text] [Related]

  • 4. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.
    Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K.
    Semin Thromb Hemost; 2009 Nov; 35(8):794-805. PubMed ID: 20169516
    [Abstract] [Full Text] [Related]

  • 5. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW, Chen LS, Jayakodi D, Dunkley SM.
    Thromb Res; 2013 Nov; 132(6):735-41. PubMed ID: 24119613
    [Abstract] [Full Text] [Related]

  • 6. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G, Jayakodi D, Dunkley S.
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [Abstract] [Full Text] [Related]

  • 7. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
    Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K, RCPA Haematology QAP Haemostasis Committee.
    Haemophilia; 2010 Jul 01; 16(4):662-70. PubMed ID: 20070382
    [Abstract] [Full Text] [Related]

  • 8. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E, Collecutt M, Street A.
    Methods Mol Biol; 2013 Jul 01; 992():321-33. PubMed ID: 23546724
    [Abstract] [Full Text] [Related]

  • 9. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I.
    Thromb Haemost; 2001 Dec 01; 86(6):1435-9. PubMed ID: 11776311
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK, Wang ZW, Hua BL, Su W, Wang SJ, Zhao YQ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct 01; 31(5):551-4. PubMed ID: 19968068
    [Abstract] [Full Text] [Related]

  • 11. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C, Desconclois C, Sobas F, Aillaud MF, Ternisien C, Caron C.
    Int J Lab Hematol; 2015 Feb 01; 37(1):125-32. PubMed ID: 24815078
    [Abstract] [Full Text] [Related]

  • 12. [Notes on laboratory coagulation testing for acquired hemophilia A].
    Amano K.
    Rinsho Byori; 2009 Oct 01; 57(10):999-1003. PubMed ID: 19928498
    [Abstract] [Full Text] [Related]

  • 13. Factor VIII inhibitors: a 50-year perspective.
    Green D.
    Haemophilia; 2011 Nov 01; 17(6):831-8. PubMed ID: 21592257
    [Abstract] [Full Text] [Related]

  • 14. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R.
    Am J Hematol; 2007 Jun 01; 82(6):460-2. PubMed ID: 17211843
    [Abstract] [Full Text] [Related]

  • 15. External quality assessment of factor VIII inhibitor assays.
    Bonar RA, Favaloro EJ, Marsden K.
    Semin Thromb Hemost; 2013 Apr 01; 39(3):320-6. PubMed ID: 23436565
    [Abstract] [Full Text] [Related]

  • 16. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E.
    Thromb Haemost; 1995 Feb 01; 73(2):247-51. PubMed ID: 7792738
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
    Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID.
    Semin Thromb Hemost; 2009 Nov 01; 35(8):778-85. PubMed ID: 20169514
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.